R V Iaffaioli
Overview
Explore the profile of R V Iaffaioli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Gridelli C, Curcio C, Iaffaioli R, Brancaccio L, DAprile M, Gebbia V, et al.
Anticancer Res
. 2002 Mar;
21(6A):4179-83.
PMID: 11911315
Unlabelled: A phase II trial was undertaken to test the activity and toxicity of carboplatin (300 mg/m2, i.v. day 1) + epirubicin (75 mg/m2, i.v. day 1) + VP-16 (100...
22.
Iaffaioli R, Tortoriello A, Gravina A, Facchini G, Turitto G, Elia S, et al.
Lung Cancer
. 2001 Jan;
30(3):203-10.
PMID: 11137206
Gemcitabine and paclitaxel are among the most active new agents in non-small cell lung cancer (NSCLC) and are worth considering for second-line chemotherapy. In this phase I-II study, we combined...
23.
Turitto G, Tortoriello A, Facchini G, Frattolillo A, Lombardi R, Moscariello E, et al.
Recenti Prog Med
. 2000 Nov;
91(10):507-10.
PMID: 11072738
Primary cutaneous plasmacytomas of the chest wall are very rare. In this report we describe a case of a 70-years old man, affected by chronic obstructive pulmonary disease and renal...
24.
Iaffaioli R, Tortoriello A, Santangelo M, Turitto G, Libutti M, Benassai G, et al.
Clin Oncol (R Coll Radiol)
. 2000 Sep;
12(4):251-5.
PMID: 11005695
Gemcitabine and paclitaxel (PTX) are among the most active new drugs in advanced breast and ovarian cancer. In this Phase I study, we used fixed doses of gemcitabine administered on...
25.
Iaffaioli R, Tortoriello A, Facchini G, Caponigro F, Gentile M, Marzano N, et al.
J Clin Oncol
. 1999 Mar;
17(3):921-6.
PMID: 10071285
Purpose: Platinum-based chemotherapy currently represents standard treatment for advanced non-small-cell lung cancer. Gemcitabine is one of the most interesting agents currently in use in advanced non-small-cell lung cancer, and high...
26.
Gridelli C, Perrone F, Ianniello G, Brancaccio L, Iaffaioli R, Curcio C, et al.
J Clin Oncol
. 1998 Apr;
16(4):1414-9.
PMID: 9552045
Purpose: To evaluate the activity and toxicity of the combination carboplatin plus vinorelbine in extensive small-cell lung cancer (SCLC). Patients And Methods: A two-stage optimal Simon design was applied. To...
27.
Tortoriello A, Facchini G, Caponigro F, Santangelo M, Benassai G, Persico G, et al.
Breast Cancer Res Treat
. 1998 Mar;
47(1):91-7.
PMID: 9493980
Paclitaxel and vinorelbine are among the most active new agents in metastatic breast cancer. Both in vitro and in vivo studies have shown that the combined administration of these two...
28.
Iaffaioli R, Facchini G, Tortoriello A, Caponigro F, Illiano A, Gentile M, et al.
Cancer Chemother Pharmacol
. 1997 Jan;
41(1):86-90.
PMID: 9443619
Background: Vinorelbine and paclitaxel interfere with mitotic spindle function through different mechanisms of action. Both of the drugs show antitumor activity in small-cell lung cancer when used as single agents;...
29.
Iaffaioli R, Caponigro F, Tortoriello A, Facchini G, Ravo V, Maccauro M, et al.
Eur J Cancer
. 1996 Oct;
32A(11):1901-4.
PMID: 8943672
43 patients with stage III NSCLC (non-small cell lung cancer) entered a phase II study aimed at evaluating the toxicity and the activity of a combined modality programme including an...
30.
Iaffaioli R, Facchini G, Tortoriello A, Scala S, Pacelli R, LA Mura G, et al.
J Exp Ther Oncol
. 1996 Jul;
1(4):226-30.
PMID: 9414408
Low-grade non-Hodgkin's lymphoma and multiple myeloma are chemosensitive malignancies, but are rarely curable because of primary or acquired drug resistance. Interferon has been shown to modulate the multidrug resistance phenotype...